loading page

Feasibility of oncology clinical trial-embedded evaluation of social determinants of health
  • +14
  • Rahela Aziz-Bose,
  • Daniel Zheng,
  • Puja Umaretiya,
  • Lenka Ilcisin,
  • Kristen Stevenson,
  • Victoria Koch,
  • Ariana Valenzuela,
  • Peter Cole,
  • Lisa Gennarini,
  • Justine Kahn,
  • Kara Kelly,
  • Bruno Michon,
  • Thai Hoa Tran,
  • Jennifer Welch,
  • Lewis Silverman,
  • Joanne Wolfe,
  • Kira Bona
Rahela Aziz-Bose
Dana-Farber Cancer Institute

Corresponding Author:[email protected]

Author Profile
Daniel Zheng
The Children's Hospital of Philadelphia
Author Profile
Puja Umaretiya
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Author Profile
Lenka Ilcisin
Brigham and Women's Hospital
Author Profile
Kristen Stevenson
Dana-Farber Cancer Institute
Author Profile
Victoria Koch
Dana-Farber Cancer Institute
Author Profile
Ariana Valenzuela
Dana-Farber Cancer Institute
Author Profile
Peter Cole
Rutgers The State University of New Jersey
Author Profile
Lisa Gennarini
The Children's Hospital at Montefiore
Author Profile
Justine Kahn
Columbia University Medical Center
Author Profile
Kara Kelly
Roswell Park Cancer Institute
Author Profile
Bruno Michon
CHU Québec-Université Laval
Author Profile
Thai Hoa Tran
CHU Sainte-Justine
Author Profile
Jennifer Welch
Hasbro Children's Hospital
Author Profile
Lewis Silverman
Dana Farber Cancer Institute
Author Profile
Joanne Wolfe
Dana Farber Cancer Institute
Author Profile
Kira Bona
Dana-Farber Cancer Institute
Author Profile


Social determinants of health (SDoH) are associated with stark disparities in cancer outcomes, but systematic SDoH data collection is currently absent from oncology clinical trials. Trial-based SDoH data are essential to ensure representation of marginalized populations, contextualize outcomes, and identify health-equity intervention opportunities. We report the feasibility of the first pediatric oncology multicenter trial-embedded SDoH investigation. Among 448 trial participants, 392 (87.5%) opted-in to the embedded SDoH study; 375 (95.7%) completed baseline surveys, with high longitudinal response rates (87.2-92.8%) over 24-months of therapy. Trial-embedded SDoH data collection is feasible and acceptable, and must be consistently included within future oncology trials.
11 Apr 2022Submission Checks Completed
11 Apr 2022Assigned to Editor
11 Apr 2022Submitted to Pediatric Blood & Cancer
12 Apr 2022Reviewer(s) Assigned
12 May 2022Review(s) Completed, Editorial Evaluation Pending
12 May 2022Editorial Decision: Revise Major
15 Jun 20221st Revision Received
15 Jun 2022Assigned to Editor
15 Jun 2022Submission Checks Completed
20 Jun 2022Reviewer(s) Assigned
19 Jul 2022Review(s) Completed, Editorial Evaluation Pending
20 Jul 2022Editorial Decision: Revise Minor
25 Jul 20222nd Revision Received
25 Jul 2022Submission Checks Completed
25 Jul 2022Assigned to Editor
29 Jul 2022Review(s) Completed, Editorial Evaluation Pending
29 Jul 2022Editorial Decision: Accept
Nov 2022Published in Pediatric Blood & Cancer volume 69 issue 11. 10.1002/pbc.29933